Autopsy report · NCT04115839
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
Cause of deathFunding or business
“Development program terminated”
Life of this trial
- Registered 1 month before it started.
- Ran for about 1 year 4 months before it stopped.
- 106 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- Psoriatic Arthritis
- Interventions
- Filgotinib; Placebo to match filgotinib
- Participants
- 106
- Sites
- 59
- Countries
- Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, South Korea, Spain, Taiwan, United States
Trials that died the same way
- GALLANT 22 Tesaglitazar vs. Placebo
“The development program has been terminated” - Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
“Program terminated” - A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
“Program Development discontinued” - Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers
“Product development project closed prematurely” - Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
“Due to a change in the development program, the study was closed prematurely.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.